Evidence map›Paper›PMID 37081729›Full record

Trial reportCancer medicine2023

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial.

Tomoaki Sonoda, Yukihiro Umeda, Yoshiki Demura, Toshihiko Tada, Koki Nakashima, Masaki Anzai, Makiko Yamaguchi, Akikazu Shimada, Masahiro Ohi, Chisato Honjo and 3 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tomoaki SonodaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yukihiro UmedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.ORCID 0000-0002-9826-6856
Yoshiki DemuraDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Toshihiko TadaDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Koki NakashimaDepartment of Respiratory Medicine, Municipal Tsuruga Hospital, Fukui, Japan.
Masaki AnzaiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Makiko YamaguchiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Akikazu ShimadaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masahiro OhiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Chisato HonjoThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yuko WasedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masaya AkaiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Tamotsu IshizukaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
University of Fukui · JPFukui Red Cross Hospital · JPMunicipal Tsuruga Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether immunotherapy improves the efficacy or worsens adverse events of subsequent chemotherapy remains unclear. We performed a Phase 2 study to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a treatment for advanced non-small cell lung cancer (NSCLC) after treatment with programmed cell death 1 or programmed death ligand 1 [PD-(L)1] inhibitor failure.

methodsNab-paclitaxel (100 mg/m

resultsThirty cases were registered, and 29 cases were included in the analysis. The ORR was 55.2% (95% confidence interval [CI]: 28.1%-79.6%) and the DCR was 86.2% (95% CI: 65.9%-97.0%). The median PFS was 5.6 months (95% CI: 4.4-6.7 months), and PFS rates at 1- and 2-year timepoints were 34.5% and 13.3%, respectively. The median OS was 11.9 months (95% CI: 0.8-23.0 months). Good performance status and responder of previous PD-(L)1 inhibitor therapy were independent predictors of PFS. Grade 3 or higher toxicities included leukopenia (27.6%), neutropenia (31.0%), peripheral sensory neuropathy (6.9%), increased alanine aminotransferase and aspartate aminotransferase levels (3.4%), and interstitial lung disease (3.4%).

conclusionsNab-paclitaxel therapy improved ORR after PD-(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNanoparticlesNeutropeniaAlbumin-Bound PaclitaxelAlbuminsAntineoplastic Combined Chemotherapy ProtocolsHumansImmune Checkpoint InhibitorsPaclitaxel130-nm albumin-bound paclitaxelAlbumin-Bound PaclitaxelAlbuminsImmune Checkpoint InhibitorsPaclitaxelimmune checkpoint inhibitornab-paclitaxelnon-small cell lung cancerprogrammed cell death 1 inhibitorprogrammed death ligand 1 inhibitor

Identifiers

PMID37081729
PMCPMC10315716
OpenAlexW4366603129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.